ARTICLE SUMMARY:
As Johnson & Johnson looks ahead, the healthcare giant sees tremendous opportunities in its core clinical spaces and a transformative role for high tech, as joint ventures with IBM and Verily attest. Medtech remains important, says CEO Alex Gorsky, because a diverse portfolio has helped J&J weather ups and downs in its different businesses over its 132-year history.
In the first part of this interview, we talked with Johnson & Johnson Chairman and CEO Alex Gorsky about some initiatives around innovation that the corporation has recently undertaken, most notably its Houston-based Center for Device Innovation (CDI) and about J&J’s plans in two of its key clinical areas: cardiovascular and orthopedics. (See “Johnson & Johnson in Medtech: An Interview with CEO Alex Gorsky,” MedTech Strategist, March 27, 2018.)
